Laura E Been, Amanda R Halliday, Sarah M Blossom, Elena M Bien, Anya G Bernhard, Grayson E Roth, Karina I Domenech Rosario, Karlie B Pollock, Petra E Abramenko, Leily M Behbehani, Gabriel J Pascal, Mary Ellen Kelly
Tamoxifen, a selective estrogen receptor modulator (SERM), is commonly used as an adjuvant drug therapy for estrogen-receptor-positive breast cancers. Though effective at reducing the rate of cancer recurrence, patients often report unwanted cognitive and affective side effects. Despite this, the impacts of chronic tamoxifen exposure on the brain are poorly understood, and rodent models of tamoxifen exposure do not replicate the chronic oral administration seen in patients. We, therefore, used long-term ad lib consumption of medicated food pellets to model chronic tamoxifen exposure in a clinically relevant way...
March 31, 2024: Cancers